Lack of Cancer Specificity of Methionine Adenosyltransferase 2A (MAT2A) Inhibitor AG-270 in Combination With Recombinant Methioninase In Vitro
Anticancer Research · 2026
DOI: 10.21873/anticanres.17980 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2026. Verfasst von Jinsoo Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: AntiCancer Inc., San Diego, CA, U.S.A. Hauptthemen laut MEDLINE: Methionine Adenosyltransferase, Carbon-Sulfur Lyases, Antineoplastic Agents, Enzyme Inhibitors.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AntiCancer Inc., San Diego, CA, U.S.A.
- Department of Surgery, University of California, San Diego, CA, U.S.A.
- Department of Surgery, Chungnam National University College of Medicine, Daejeon, Republic of Korea.
- AntiCancer Inc., San Diego, CA, U.S.A.; all@anticancer.com.
Zitieren
APA
Kim, J., Han, Q., Li, S., Kang, B. M., Mizuta, K., Asano, Y., Miyashi, Y., Bouvet, M., & Hoffman, R. M. (2026). Lack of Cancer Specificity of Methionine Adenosyltransferase 2A (MAT2A) Inhibitor AG-270 in Combination With Recombinant Methioninase In Vitro. Anticancer Research. https://doi.org/10.21873/anticanres.17980
Vancouver
Kim J, Han Q, Li S, Kang BM, Mizuta K, Asano Y, et al. Lack of Cancer Specificity of Methionine Adenosyltransferase 2A (MAT2A) Inhibitor AG-270 in Combination With Recombinant Methioninase In Vitro. Anticancer Research. 2026. doi:10.21873/anticanres.17980
BibTeX
@article{Kim2026,
author = {Kim, Jinsoo and Han, Qinghong and Li, Shukuan and Kang, Byung Mo and Mizuta, Kohei and Asano, Yohei and Miyashi, Yuta and Bouvet, Michael and Hoffman, Robert M},
title = {Lack of Cancer Specificity of Methionine Adenosyltransferase 2A (MAT2A) Inhibitor AG-270 in Combination With Recombinant Methioninase In Vitro},
journal = {Anticancer Research},
year = {2026},
doi = {10.21873/anticanres.17980}
}
EUVIMED